Thanks to our close relationship with vendors and manufacturers, we have the unique capability to find niche products and hard to find medicines. You can rely on us for getting the newest approved products in the market and those not yet available in some countries. Our range of products is so wide, you won’t need to look for other suppliers.
with a wide clients’ base made of hospitals, private clinics, pharmacies and distributors, we have developed a deep knowledge of what the needs, constraints and priorities are for each or our client. That is why we understand your urgency and we can fully meet your demands with the highest standards of service.
Our stringent operating procedures guarantee every step of handling, storage and distribution of all medicinal products.
When you contact us in Elixi, you know you are getting the best customer service: our dedicated people will offer you quick responses, personalised approach and bespoke solutions. Our approach is not to follow only standard procedures but taking care of every specific detail and taking to heart every request and individual issues.
Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value. Our team has the knowledge and familiarity needed to achieve the best possible results in the quickest time and at the best price.
The U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy
The U.S. Food and Drug Administration has approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less
The U.S. Food and Drug Administration has approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of
The U.S. Food and Drug Administration has announced the approval of Dengvaxia, the first vaccine approved for the prevention of
The U.S. Food and Drug Administration has approved Benlysta (belimumab) intravenous (IV) infusion for treatment of children with systemic lupus
Bristol-Myers Squibb has announced results from pooled analyses of survival data from four studies in patients with previously-treated advanced non-small cell
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040
